Archives

Why do we need biomarkers for Alzheimer’s disease?

29 September 2016

Professor Simon Lovestone, Professor of Translational Neuroscience at the University of Oxford

This blog was written by Professor Simon Lovestone, Professor of Translational Neuroscience at the University of Oxford and was originally featured on the NIHR website.    There is an increasing focus on finding biomarkers, or tests, for dementia. Whether in the contents pages of journals, or in conference programmes, biomarker research seems to be the order […]

The ENGAGE study

19 July 2016

Professor Craig Ritchie

The latest clinical trial to be added to Join Dementia Research is ENGAGE, from Biogen Inc. Part of an international study, it is looking to determine whether a new medication called Aducanumab, can slow progression of early Alzheimer’s disease, as well as investigating whether it’s safe to use in patients. Researchers are looking for volunteers […]

Number of Alzheimer’s clinical trials almost doubles in 3 years

JDR vounteer animation still

According to latest figures, the number of drug trials to treat Alzheimer’s disease across the globe has almost doubled since 2013¹. In the UK, there are now 19 drug studies investigating potential new treatments for Alzheimer’s and other dementias², testing treatments that aim to be the first to slow or stop the progression of the […]

The DARet Study

11 July 2016

Hanna Isotalus, Study Coordinator for the DARet Study

Sometimes patients treated for Parkinson’s disease can have problems with memory and learning. This is thought to be due to a decrease in their dopamine levels due to their disease. Dopamine is a naturally occurring chemical in the brain. Patients with Parkinson’s disease are given many drugs to increase their dopamine levels back to normal, […]

INMiND-02 Study

6 June 2016

INMiND_Logo

The INMiND-02 Study is a new trial looking at whether a drug that is currently used to treat arthritis could help the memory function of people with Mild Cognitive Impairment (MCI). What are the main aims of the INMiND-02 study? To see if a drug (Etanercept) already used for the treatment of rheumatoid arthritis might […]

MINDSET Study

19 May 2016

Dr. Lawrence Friedhoff, who previously led the development of Aricept® (donepezil), is now leading the development of RVT-101, the investigational medication in the MINDSET study.

The MINDSET Study, sponsored by Axovant Sciences Ltd., is a new study looking at whether an innovatory new drug could be used to help improve the everyday lives of mild-to-moderate Alzheimer’s patients. What are the main aims? The purpose of this study is to understand whether an investigational drug known as ‘RVT 101’ improves Alzheimer’s […]

The ‘AFFECT’ Study

26 February 2016

The ‘AFFECT’ study is the first large-scale research study that is a collaboration between researchers in Northern Ireland, and staff at the Dementias and Neurodegenerative Specialty  in England. It is also being jointly funded by the Alzheimer’s Society and British Heart Foundation. Did you know that after Alzheimer’s Disease, Vascular Dementia is the most common […]

The Gantenerumab Trial

This study looks at an exciting opportunity to get involved in testing  new medication for people with Alzheimer’s Disease. Aims of the Study Alzheimer’s disease is a major global public health problem, and there are nearly 30 million people with the disease worldwide. Alzheimer’s disease is an irreversible, progressive neurodegenerative disease which causes a gradual […]

New Alzheimer’s disease drug trial opens across Scotland

24 November 2015

radar2 (1)

People with Alzheimer’s disease who live in Scotland are being asked to consider taking part in the ground-breaking government-funded RADAR trial.  The trial is investigating if a drug normally used to treat high blood pressure (hypertension) has additional properties that could slow down the progression of Alzheimer’s disease (AD) in people with and without hypertension. […]

Could new drug slow down deterioration of the brain?

18 August 2015

logoPrimary

The AMARANTH STUDY will test whether the experimental drug, AZD3293 [LY3314814], slows the worsening of Alzheimer’s disease, compared to a placebo given to patients with Mild Cognitive Impairment (MCI) or Early Alzheimer’s disease. It’s for people aged between 55-85 and is being conducted at several places across the UK, as well as worldwide, to find out if this […]

1 2
get_header(); ?>

Archives

1 2